

# the **ADBL** report

Issue #97, July 2017

An Official Accompaniment to the Alberta Drug Benefit List (ADBL) produced by Alberta Blue Cross  
The Expert Committee on Drug Evaluation and Therapeutics (ECDET)

#### EXPERT COMMITTEE MEMBERS:

Scott Klarenbach, MD, MSc (Health Econ), FRCPC (Chair)  
Saibal Nandy, MBBS, MRCPsych, FRCPC (Vice-Chair)  
Caitlin A. Clarke, BScPhm, PharmD  
Fiona Clement, PhD  
Glen J. Pearson, BScPhm, PharmD, FCSHP  
Cheryl A. Sadowski, BSc (Pharm), PharmD, FCSHP  
Jeremy Slobodan, BSP

#### ALBERTA HEALTH LIAISONS:

Chad Mitchell, BSc Pharm, MSc

#### ADMINISTRATIVE AND SCIENTIFIC SUPPORT:

Amanda Chung, BSc (Pharm)  
Sherry Dieleman, BSc (Pharm), MSc  
Connie Lussier, BSP, MA  
Carlyn Volume-Smith, BSc (Pharm), MSc, PhD  
Darcia Wasarab-Rolland, BSc (Pharm)

## In this issue:

- *Brief Summary of Drug Review Activities*
- *Highlights of:*
  - ❖ *Products Originally Reviewed via the CDR*
  - ❖ *Devices added*
  - ❖ *Interchangeable Drug Products added*
  - ❖ *Non-Interchangeable Old Drug Products added*

## *Brief Summary of Drug Review Activities*

The Expert Committee on Drug Evaluation and Therapeutics met on May 15 & 16, 2017. The Committee reviewed Manufacturer submissions for twenty-four (24) Drug Products for potential listing, or change in listing, on the ADBL. The Committee also considered information for a number of supplementary assessments of the coverage status of twenty-four (24) Drug Products.

In addition to Drug Products reviewed by the Expert Committee, twenty-three (23) Drug Products underwent Expedited Review for listing on the ADBL effective July 1, 2017.

The following are highlights of recent changes to the ADBL and other topics of general interest. A complete list of changes, as well as the full ADBL may be accessed at <https://www.ab.bluecross.ca/dbl/publications.html>

## *Highlights of Products Originally Reviewed via the Common Drug Review (CDR)*

The following Drug Products were reviewed by CDR and the Expert Committee and added to the ADBL via Special Authorization, effective July 1, 2017:

- **ENTYVIO\*** (vedolizumab) (TAK) **300 mg/vial injection**
- **FERRIPROX\*** (deferiprone) (APP) **1000 mg tablet & 100 mg/mL oral solution**
- **PLEGRIDY\*** (peginterferon beta-1a) (BIO) **63 mcg/94 mcg starter pack & 125 mcg pre-filled syringes/pens**

In keeping with recommendations from the CDR, the following Drug Products have NOT been added to the ADBL:

- **CORTIMENT** (budesonide) (FEI) **9 mg delayed and extended release tablet**
- **FENTORA** (fentanyl) (TMP) **100 mcg, 200 mcg, 400 mcg, 600 mcg & 800 mcg buccal/sublingual effervescent tablets**

A complete list of changes, as well as the full ADBL may be accessed at <https://www.ab.bluecross.ca/dbl/publications.html>.

\*Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).\*

## *Highlights of Devices Added*

The following Device was added as a Restricted Benefit to the *ADBL* effective July 1, 2017 after a Full review by the Expert Committee:

- **AEROCHAMBER PLUS FLOW-VU CHAMBER\*** (anti-static valved holding chamber/mask) (TMI) **with adult small mask**

## *Highlights of Interchangeable (IC) Drug Products Added*

Addition of the following Expedited Entry IC Drug Products to the *ADBL* has resulted in the creation of New IC Groupings, effective July 1, 2017:

- **OLMESARTAN** (olmesartan medoxomil) (APH, APX, AUR, JPC and SDZ) **20 mg & 40 mg tablets**
- **OLMESARTAN/HCTZ** (olmesartan medoxomil/hydrochlorothiazide) (APH and APX) **20 mg/12.5 mg, 40 mg/12.5 mg & 40 mg/25 mg tablets**

## *Highlights of Non-Interchangeable Old Drug Products Added*

The following Non-Interchangeable Old Drug Product has been added to the *ADBL* effective July 1, 2017:

- **LIDODAN** (lidocaine hydrochloride) (ODN) **2% topical jelly**

A complete list of changes, as well as the full *ADBL* may be accessed at <https://www.ab.bluecross.ca/dbl/publications.html>.

\*Please refer to the current *ADBL* for explanations of coverage, including a listing of coverage criteria (where applicable).\*